A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Trial Profile

A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Esomeprazole/naproxen (Primary) ; Naproxen
  • Indications Ankylosing spondylitis; Arthritis; Duodenal ulcer; Dyspepsia; Gastric ulcer; Heartburn; Musculoskeletal pain; NSAID-induced gastric damage; NSAID-induced ulcer; Osteoarthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Sponsors POZEN
  • Most Recent Events

    • 11 Oct 2010 VIMOVO (naproxen/ esomeprazole magnesium) received positive agreement for approval, based on the results of this trial, in 23 countries across the European Union, according to an astrazeneca media release.
    • 30 Apr 2010 Exomeprazole/naproxen has been approved by the FDA according to an AstraZeneca media release. The approval was based on results from a clinical programme including results from this trial.
    • 28 Oct 2009 Key secondary endpoint data presented at the 74th Annual Scientific Meeting of the American College of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top